Biocon reports more than double revenue from Biologics in Q2FY19

26 Oct 2018 Evaluate

Biocon has reported more than double revenue from the Biologics segment, comprising Novel Biologics and Biosimilars, at Rs 367 crore in Q2FY19. The growth was driven by the commercial launch of biosimilar Pegfilgrastim in the US and strong sales of Insulins as well as biosimilar MAbs in key emerging markets.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

376.00 -1.55 (-0.41%)
19-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1166.45
Cipla 1391.20
Zydus Lifesciences 881.10
Lupin 2178.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×